Sydney, Australia 4 April 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce the appointment of David Green as Chief Financial Officer (CFO). Outgoing CFO Robert Vickery will continue to serve as Company Secretary. Mr Green joins Clarity with over…
Sydney, Australia 28 March 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that the diagnostic 64Cu SAR-bisPSMA trial (COBRA NCT052491271) for patients with prostate cancer is open for recruitment. COBRA (COpper-64 SAR-BisPSMA in Biochemically Recurrent prostAte cancer) is a Phase I/II Positron Emission…
Sydney, Australia 24 March 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that an investigator-initiated trial (IIT) will commence shortly in the US investigating 64Cu SAR-bisPSMA in prostate cancer (NCT05286840)1. The X-Cancer’s investigator-led trial of SAR-bisPSMA…
Sydney, Australia 28 February 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to provide an update regarding the Company’s negotiations with China Grand Pharmaceutical and Healthcare Holdings Limited (China Grand). As noted in the Company’s Prospectus, Clarity and China Grand agreed…
Sydney, Australia 25 February 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that it has successfully treated its first participant in cohort 2 of the 64Cu/67Cu SARTATE™ neuroblastoma therapy trial (CL04) at the increased dose level of 175MBq/kg body…
Sydney, Australia 7 February 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that it has received a confirmation from the US Food and Drug Administration (FDA) that the diagnostic 64Cu SAR-bisPSMA trial (COBRA) may proceed. Clarity’s Executive Chairman, Dr…
Sydney, Australia 4 February 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that it has received a $3,262,861 Research and Development (R&D) tax refund as part of the Australian Federal Government’s R&D tax incentive, recognising the R&D undertaken by Clarity…
Sydney, Australia 3 February 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, wishes to address recent enquiries made to the company and in the media1,2,3 regarding the outage at the High Flux Reactor (HFR) in Petten, Netherlands. On 24 January 2022, the Nuclear…
Sydney, Australia 1 February 2022 Cohort 1 completed in 3 participants with neuroblastoma who received therapy with 67Cu SARTATE™ at a dose of 75MBq/kg body weight No dose limiting toxicities (DLTs) have been reported in cohort 1 The Safety Review Committee (SRC) has recommended the trial continues with the dose escalation phase as planned Recruitment…
Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to release its first Annual Newsletter as a listed entity for the calendar year ending 31 December 2021. To read the Year in Review 2021 Newsletter, click here, About Clarity Clarity is a…